Year of Appointment
|Andrea Pfeifer, Ph.D.
||Chief Executive Officer and Director
Chief Financial Officer
Chief Administrative Officer
|Marie Kosco-Vilbois, Ph.D.
||Chief Scientific Officer
||Head of Technical Operations and Program Management
|Sonia Poli, Ph.D.
||Head of Translational Science
|Other Key Employees
|Olivier Sol, M.D.
||Head of Clinical Team
|Julian Gray, M.D., Ph.D.
||Chairman and Director
|Detlev Riesner, Ph.D.
|Friedrich von Bohlen und Halbach, Ph.D.
|Peter Bollmann, Ph.D.
|Douglas Williams, Ph.D.
|Werner Lanthaler, Ph.D.
The current business addresses for our
executive officers, other key employees, directors and director nominee is AC Immune SA, EPFL Innovation Park, Building B, 1015
Andrea Pfeifer, Ph.D., Co-Founder, Chief
Executive Officer and Director: Dr. Pfeifer co-founded AC Immune in April 2003, and has served as a director on our board
since our IPO. Prior to founding us, Dr. Pfeifer was head of Nestlé’s Global Research in Lausanne, Switzerland.
While at Nestlé, she led the scientific development of the first Functional Food, LC1, and one of the first Cosmoceutical
products in a joint venture with L’Oreal, Innéov Fermeté. She also co-founded the Nestlé Venture Capital
Fund, a Life Sciences corporate venture fund. She serves as chairwoman of Investment Fund BioMedInvest, Basel and AB2 Bio, Lausanne
and is a member of the Supervisory Board of Symrise AG, Holzminden. Dr. Pfeifer is a member of the CEOi Initiative on Alzheimer’s
Dr. Pfeifer holds a Ph.D. in Toxicology,
Cancer Research from the University of Würzburg, Germany. She continued with post-doctoral work in Molecular Carcinogenesis
at the National Institutes of Health, Human Carcinogenesis Branch, in Bethesda, Maryland. Dr. Pfeifer is a registered toxicologist
and pharmacist. She received her habilitation from the University of Lausanne, Switzerland and is also an honorary professor at
the École Polytechnique Fédérale de Lausanne (EPFL).
Joerg Hornstein, Chief Financial
Officer: Mr. Hornstein has served as our Chief Financial Officer since April 2017. Prior to joining AC Immune, Mr. Hornstein
served as Senior Vice President Group Controlling for Unternehmensgruppe Theo Müller based in Luxembourg from January 2014
to March 2017. Between 2002 and 2013 he worked for Merck KGaA, a leading science and technology company in healthcare, life science
and performance materials, where he held various senior finance roles. Amongst others, he was CFO for Merck’s operations
in Indonesia and Merck Serono’s operations in China. Furthermore, he served as Vice President Group Controlling for Merck
Group Headquarters in Germany and as Divisional CFO for Merck Millipore in the U.S. Mr. Hornstein holds an MBA with Distinction
from London Business School, UK, and a Bachelor of Business Administration from Baylor University in the U.S.
Jean-Fabien Monin, Chief Administrative
Officer: Mr. Monin was nominated Chief Administrative Officer in July 2015 following his role as our Chief Financial Officer
from March 2009 to July 2015. Prior to AC Immune, he held several positions during his tenure of 14 years at bioMérieux,
a leading international in vitro diagnostics group, culminating in his nomination as Chief Financial Officer. His last position
was CFO of bioMérieux Central Europe based in Vienna, Austria from December 2006 to March 2009. Mr. Monin holds a Masters
in Finance and International Business from the University of Paris-Dauphine, France.
Marie Kosco-Vilbois, Ph.D., Chief
Scientific Officer: A US citizen, Dr. Kosco-Vilbois has extensive experience in the biopharmaceutical industry and served
as Chief Scientific Officer of Novimmune since 2005. Prior to joining Novimmune in 2002, Dr. Kosco-Vilbois was Head of
Immunology and Preclinical Pharmacology at the Serono Pharmaceutical Research Institute, a Senior Scientist and then Head of
Immunology at the Glaxo Wellcome Research Institute in Geneva and a Scientific Member of the Basel Institute for Immunology.
During her career, she has taken numerous Biologicals from discovery into pre-clinical studies and clinical development, most
notably filing market applications of a Biological for an Orphan indication. Dr. Kosco-Vilbois gained her Bachelor's Degree
in Biology from Rutgers University, New Jersey, US, and a PhD in Anatomy and Immunology from the Medical College of
Virginia/Virginia Commonwealth University School of Medicine, US.